Vilsbøll, T <br/><br/>
Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Apr 2012 
 - 41-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/j.1463-1326.2012.01579.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Blood Glucose--drug effects<br/>Blood Pressure--drug effects<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Female<br/>Glucagon-Like Peptide 1--analogs & derivatives<br/>Glucagon-Like Peptide-1 Receptor<br/>Humans<br/>Hypertension--drug therapy<br/>Incretins--metabolism<br/>Insulin-Secreting Cells--drug effects<br/>Liraglutide<br/>Male<br/>Neuroprotective Agents--pharmacology<br/>Receptors, Glucagon--agonists<br/>Weight Loss--drug effects